SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca announced a clinical trial collaboration with Merck to evaluate…

Erasca, Inc. · PRESS-RELEASE filed May 11, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 11, 2026 at 07:00 ET

Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA for RAS-mutant solid tumors. Merck will supply pembrolizumab at no cost, and Erasca will sponsor the AURORAS-1 study. This is a non-financial collaboration that provides validation for Erasca's pipeline but does not change the company's fundamental outlook.

  • Erasca entered a clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA in RAS-mutant solid tumors.
  • Merck is supplying pembrolizumab at no cost; Erasca sponsors the AURORAS-1 study.
  • ERAS-0015 is an oral pan-RAS molecular glue with early Phase 1 data showing favorable safety and partial responses at doses as low as 8 mg QD.
  • Approximately 2.7 million patients are diagnosed annually with RAS-mutant tumors worldwide.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access